Effect of atorvastatin monotherapy and low-dose atorvastatin/ezetimibe combination on fasting and postprandial triglycerides in combined hyperlipedemia

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 17, Issue 1, 2012, Pages 65-71

  Lee, Sang Hak ^a   Park, Sungha ^a   Kang, Seok Min ^a   Jang, Yangsoo ^a   Chung, Namsik ^a   Choi, Donghoon ^a  

^a Yonsei University   (South Korea)

Author keywords

atorvastatin; ezetimibe; hypertriglyceridemia; postprandial period

Indexed keywords

ATORVASTATIN; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BODY FAT; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; AZETIDINES; DRUG THERAPY, COMBINATION; FASTING; FEMALE; HEPTANOIC ACIDS; HUMANS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; PYRROLES; TREATMENT OUTCOME; TRIGLYCERIDES; YOUNG ADULT;

EID: 84863011598     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248411399762     Document Type: Article

References (26)

1. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial). Am J Cardiol. 2003 ; 92 (2). 152-160 (Pubitemid 36835963)
2. Deedwania PC, Hunninghake DB, Bays HE, Jones PH, Cain VA, Blasetto JW.. Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome. Am J Cardiol. 2005 ; 95 (3). 360-366 (Pubitemid 40164540)
3. Tremblay AJ, Lamarche B, Cohn JS, Hogue JC, Couture P.. Effect of ezetimibe on the in vivo kinetics of apob-48 and apob-100 in men with primary hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2006 ; 26 (5). 1101-1106 (Pubitemid 43732118)
4. Gagne C, Gaudet D, Bruckert E.. Efficacy and safety of ezetimibe coadministratered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation. 2002 ; 105 (21). 2469-2475 (Pubitemid 34568966)
5. Kastelein JJ, Akdim F, Stroes ES, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008 ; 358 (14). 1431-1443 (Pubitemid 351482735)
6. Rossebo AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008 ; 359 (13). 1343-1356
7. Taylor AJ, Villines TC, Stanek EJ, et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med. 2009 ; 361 (22). 2113-2122
8. Nordestgaard BG, Benn M, Schnohr P, Tybjarg-Hansen A.. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007 ; 298 (3). 299-308 (Pubitemid 47080484)
9. Eberly LE, Stamler J, Neaton JD.. Relation of triglyceride levels, fasting and nonfasting, to fatal and nonfatal coronary heart disease. Arch Intern Med. 2003 ; 163 (9). 1077-1083 (Pubitemid 36548936)
10. van Wijk JP, Halkes CJ, de Jaegere PP, Plokker HW, Erkelens DW, Cabezas MC.. Normalization of daytime triglyceridemia by simvastatin in fasting normotriglyceridemic patients with premature coronary sclerosis. Atherosclerosis. 2003 ; 171 (1). 109-116 (Pubitemid 37464635)
11. Karpe F.. Postprandial lipemia-effect of lipid-lowering drugs. Atherosclerosis Suppl. 2002 ; 3 (1). 41-46
12. Masuda D, Nakagawa-Toyama Y, Nakatani K, et al. Ezetimibe improves postprandial hyperlipidemia in patients with type IIb hyperlipidemia. Eur J Clin Invest. 2009 ; 39 (8). 689-698
13. Olijhoek JK, Hajer GR, van der Graaf Y, Dallinga-Thie GM, Visseren FL.. The effects of low-dose simvastatin and ezetimibe compared to high-dose simvastatin alone on post-fat load endothelial function in patients with metabolic syndrome: a randomized double-blind crossover trial. J Cardiovasc Pharmacol. 2008 ; 52 (2). 145-150
14. Hajer GR, Dallinga-Thie GM, van Vark-van der Zee LC, Visseren FL.. The effect of statin alone or in combination with ezetimibe on postprandial lipoprotein composition in obese metabolic syndrome patients. Atherosclerosis. 2009 ; 202 (1). 216-224
15. Piorkowski M, Fischer S, Stellbaum C, et al. Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets?. J Am Coll Cardiol. 2007 ; 49 (10). 1035-1042 (Pubitemid 46349499)
16. Liu PY, Liu YW, Lin LJ, Chen JH, Liao JK.. Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on Rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation. Circulation. 2009 ; 119 (1). 131-138
17. Cabezas MC, Verseyden C, Meijssen S, Jansen H, Erkelens DW.. Effects of atorvastatin on the clearance of triglyceride-rich lipoproteins in familial combined hyperlipidemia. J Clin Endocrinol Metab. 2004 ; 89 (12). 5972-5980 (Pubitemid 39628402)
18. Parhofer KG, Laubach E, Barrett PH.. Effect of atorvastatin on postpranial lipoprotein metabolism in hypertriglyceridemic patients. J Lipid Res. 2003 ; 44 (6). 1192-1198 (Pubitemid 37279637)
19. Guerin M, Egger P, le Goff W, Soudant C, Dupuis R, Chapman MJ.. Atorvastatin reduces postprandial accumulation and cholesteryl ester transfer protein-mediated remodeling of triglyceride-rich lipoprotein subspecies in type IIb hyperlipidemia. J Clin Endocrinol. Metab. 2002 ; 87 (11). 4991-5000 (Pubitemid 35316337)
20. Sandoval JC, Nakagawa-Toyama Y, Masuda D, et al. Molecular mechanisms of ezetimibe-induced attenuation of postprandial hypertriglyceridemia. J Atheroscler Thromb. 2010 ; 17 (9). 914-924
21. Feldman T, Koren M, Insull W, et al. Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals. Am J Cardiol. 2004 ; 93 (12). 1481-1486 (Pubitemid 38749203)
22. Denke M, Pearson T, McBride P, Gazzara RA, Brady WE, Tershakovec AM.. Ezetimibe added to ongoing statin therapy improves LDL-C goal attainment and lipid profile in patients with diabetes or metabolic syndrome. Diab Vasc Dis Res. 2006 ; 3 (2). 93-102 (Pubitemid 44638383)
23. Her AY, Kim JY, Kang SM, et al. Effects of atorvastatin 20 mg, rosuvastatin 10 mg, and atorvastatin/ezetimibe 5 mg/5 mg on lipoproteins and glucose metabolism. J Cardiovasc Pharm Ther. 2010 ; 15 (2). 167-174
24. Basso F, Freeman LA, Ko C, et al. Hepatic ABCG5/G8 overexpression reduces apoB-lipoproteins and atherosclerosis when cholesterol absorption is inhibited. J Lipid Res. 2007 ; 48 (1). 114-126 (Pubitemid 46052903)
25. Telford DE, Sutherland BG, Edwards JY, Andrews JD, Barrett PH, Huff MW.. The molecular mechanisms underlying the reduction of LDL apoB-100 by ezetimibe plus simvastatin. J Lipid Res. 2007 ; 48 (3). 699-708 (Pubitemid 46397473)
26. Warnick GR, Nakajima K.. Fasting versus nonfasting triglycerides: implications for laboratory measurements. Clin Chem. 2008 ; 54 (1). 14-16 (Pubitemid 351182591)